Chiasma Revenue and Competitors
Estimated Revenue & Valuation
- Chiasma's estimated annual revenue is currently $2M per year.
- Chiasma's estimated revenue per employee is $77,500
- Chiasma's total funding is $246M.
Employee Data
- Chiasma has 26 Employees.
- Chiasma grew their employee count by -4% last year.
Chiasma's People
| Name | Title | Email/Phone |
|---|
Chiasma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $23.9M | 150 | 4% | N/A | N/A |
What Is Chiasma?
Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company?s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company?s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary.
keywords:N/A
$246M
Total Funding
26
Number of Employees
$2M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Chiasma News
Novartis; Aegis Therapeutics; Chiasma; Crinetics Pharmaceuticals; Daewoong Pharmaceutical; Peptron; Silence Therapeutics; Strongbridge Biopharma...
Somatostatin Analogs Sales Market Size 2022-2030| Key Players Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical. Market Size And Forecast. New Jersey, USA,-...
Chiasma Inc; Novartis AG; Ipsen Biopharmaceuticals Inc; Wockhardt Ltd. Troikaa Pharmaceuticals Limited; VHB Life Sciences Limited; GlaxoSmithKline plc.
Chiasma, Inc., a U.S. privately-held biopharma company, closed a $70m Series E financing round. Backers included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as existing investors MPM Capital, F2 Capital, 7 Med Health Ve ...
Roche initially held a $595 million commercialization deal with Chiasma, but cancelled it this August, according to Israeli business publication Globes. It writes: In a conference call, Roche explained that in view of its 1st half results, reported on July 27, while the product had achieved goo ...
Other Companies in Needham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.8M | 27 | -55% | N/A |
#2 | $4.2M | 27 | -7% | N/A |
#3 | $4M | 28 | N/A | N/A |
#4 | $2.9M | 29 | 7% | N/A |
#5 | $3M | 29 | -6% | N/A |